Targeted therapies in atopic dermatitis: toward endotype-driven precision medicine and disease modification
4 affiliations
- 1Department of Plastic and Aesthetic Surgery, Lishui Traditional Chinese Medicine Hospital
- 2Lishui Central Hospital, Shaoxing University
- 3Department of Gastrointestinal Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- 4Gongji Gastrointestinal Tumor Research Institute, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Abstract
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease driven by a combination of genetic predisposition, epidermal barrier dysfunction, immune dysregulation, aberrant neuroinflammatory signaling, and environmental factors. Genetic defects in barrier-related molecules, particularly loss-of-function mutations in filaggrin (FLG), represent key heritable determinants of impaired epidermal integrity and enhanced allergen penetration. In recent years, advances in the understanding of its molecular pathogenesis have progressively shifted the therapeutic paradigm from conventional broad-spectrum immunosuppression toward precision-targeted interventions aimed at key inflammatory pathways, substantially transforming disease management in patients with moderate-to-severe AD. Current evidence indicates that type 2 immune inflammation remains a central pathogenic axis in AD. Key mediators, including interleukin (IL)-4, IL-13, IL-31, thymic stromal lymphopoietin (TSLP), and the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling pathway, collectively contribute to epidermal barrier disruption, inflammatory amplification, and the itch–scratch cycle. Based on these mechanisms, a range of biologics and small-molecule targeted therapies—including IL-4 receptor α (IL-4Rα) antagonists, IL-13 monoclonal antibodies, IL-31 pathway inhibitors, JAK inhibitors, and emerging OX40/OX40L modulatory strategies—have demonstrated significant efficacy in randomized controlled trials and real-world studies, thereby ushering AD into a mechanism-driven therapeutic era. However, targeted therapies still face critical challenges, including heterogeneous treatment responses, insufficient long-term safety data, limited stratification of disease endotypes, and disparities in treatment accessibility. Increasing evidence suggests that therapeutic response is more closely associated with immunological endotypes than traditional clinical phenotypes, and that single-pathway blockade alone is insufficient to achieve durable disease modification. This review systematically summarizes the key pathogenic mechanisms of AD, current targeted therapeutic strategies, and their clinical translation progress, with a particular focus on existing therapeutic challenges and future directions. Ultimately, integration of biomarkers, multi-omics profiling, real-world evidence, and artificial intelligence–assisted decision-making may facilitate the development of endotype-based precision treatment frameworks, enabling a shift from disease control toward sustained remission and true disease modification.
Related
- Decoding molecular heterogeneity in lupus nephritis: integrating single-cell and spatial multi-omics for endotype-driven precision therapeutics
- Comparative efficacy and safety of systemic therapies for moderate-to-severe atopic dermatitis in adults: a systematic review of randomized controlled trials
- Editorial: Targeted therapies in gastric cancer: molecular signatures and immune microenvironment insights
- BUB signaling in cancer and molecular insights into targeted therapies
- Immunomodulatory and targeted therapies for metastatic colorectal cancer
BibTeX
@article{song2026targeted,
title = {{Targeted therapies in atopic dermatitis: toward endotype-driven precision medicine and disease modification}},
author = {Wei Song and Xiaorui Yao and Changzhen Lei and Shiya Yao},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1959035},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1959035/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeted therapies in atopic dermatitis: toward endotype-driven precision medicine and disease modification
AU - Wei Song
AU - Xiaorui Yao
AU - Changzhen Lei
AU - Shiya Yao
PY - 2026
DA - 2026/10/07
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1959035
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1959035/full
AB - Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease driven by a combination of genetic predisposition, epidermal barrier dysfunction, immune dysregulation, aberrant neuroinflammatory signaling, and environmental factors. Genetic defects in barrier-related molecules, particularly loss-of-function mutations in filaggrin (FLG), represent key heritable determinants of impaired epidermal integrity and enhanced allergen penetration. In recent years, advances in the understanding of its molecular pathogenesis have progressively shifted the therapeutic paradigm from conventional broad-spectrum immunosuppression toward precision-targeted interventions aimed at key inflammatory pathways, substantially transforming disease management in patients with moderate-to-severe AD. Current evidence indicates that type 2 immune inflammation remains a central pathogenic axis in AD. Key mediators, including interleukin (IL)-4, IL-13, IL-31, thymic stromal lymphopoietin (TSLP), and the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling pathway, collectively contribute to epidermal barrier disruption, inflammatory amplification, and the itch–scratch cycle. Based on these mechanisms, a range of biologics and small-molecule targeted therapies—including IL-4 receptor α (IL-4Rα) antagonists, IL-13 monoclonal antibodies, IL-31 pathway inhibitors, JAK inhibitors, and emerging OX40/OX40L modulatory strategies—have demonstrated significant efficacy in randomized controlled trials and real-world studies, thereby ushering AD into a mechanism-driven therapeutic era. However, targeted therapies still face critical challenges, including heterogeneous treatment responses, insufficient long-term safety data, limited stratification of disease endotypes, and disparities in treatment accessibility. Increasing evidence suggests that therapeutic response is more closely associated with immunological endotypes than traditional clinical phenotypes, and that single-pathway blockade alone is insufficient to achieve durable disease modification. This review systematically summarizes the key pathogenic mechanisms of AD, current targeted therapeutic strategies, and their clinical translation progress, with a particular focus on existing therapeutic challenges and future directions. Ultimately, integration of biomarkers, multi-omics profiling, real-world evidence, and artificial intelligence–assisted decision-making may facilitate the development of endotype-based precision treatment frameworks, enabling a shift from disease control toward sustained remission and true disease modification.
SN - 1664-3224
ER -